Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues
License revenue	$ 328	$ 100
Reagent sales	59	104
Grant revenue	6	440
Total revenues	393	644
Costs of revenues
Licensing costs (including amounts to related parties)	66	20
Costs of reagent sales (including amounts to related parties)	30	33
Research and development (including amounts to related parties)	6,183	2,791
General and administrative (including amounts to related parties)	5,479	1,716
Other operating expenses (income)	(114)	77
Total operating expenses	11,644	4,637
Loss from operations	(11,251)	(3,993)
Other Income (Expense)
Investment income	483	2
Interest expense		(20)
Total other income (expense)	483	(18)
Net loss	(10,768)	(4,011)
Other Comprehensive Income
Unrealized gain on available-for-sale securities	994
Total other comprehensive income	994
Comprehensive loss	(9,774)	(4,011)
Reconciliation of net loss to net loss applicable to common stockholders
Net loss	(10,768)	(4,011)
Net decretion and dividends on convertible preferred stock		755
Net gain on extinguishment of convertible preferred stock		759
Net loss applicable to common stockholders	$ (10,768)	$ (2,497)
Basic and diluted net loss per common share	$ (0.41)	$ (0.94)
Weighted-average basic and diluted common shares	26,327	2,645